1 Low dose prime and delayed boost can improve COVID-19 vaccine efficacies by 2 increasing B cell selection stringency in germinal centres

3
4 Amar K. Garg^{1,#}, Soumya Mittal¹, Pranesh Padmanabhan², Rajat Desikan^{1,‡}, Narendra M. Dixit^{1,3,*}

5
6 ¹Department of Chemical Engineering, Indian Institute of Science, Bangalore, India 560012

7 ²Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland,
8 Brisbane, Australia 4072

9 ³Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore, India 560012

10 [#]Current Address: Helmholtz Centre for Infection Research, Braunschweig, Germany

11 [‡]Current Address: Certara QSP, Certara UK Limited, Sheffield, UK

12
13 ***Correspondence:**

14 Narendra M. Dixit

15 Email: narendra@iisc.ac.in

16 Address: Department of Chemical Engineering, Indian Institute of Science, Bangalore, 560012, Karnataka,
17 India

18

19

20

21

22

23 ABSTRACT

24 The efficacy of COVID-19 vaccines appears to depend in complex ways on the vaccine dosage
25 and the interval between the prime and boost doses. Unexpectedly, lower dose prime and longer
26 prime-boost intervals have yielded higher efficacies in clinical trials. To elucidate the origins
27 of these effects, we developed a stochastic simulation model of the germinal centre (GC)
28 reaction and predicted the antibody responses elicited by different vaccination protocols. The
29 simulations predicted that a lower dose prime could increase the selection stringency in GCs
30 due to reduced antigen availability, resulting in the selection of GC B cells with higher affinities
31 for the target antigen. The boost could relax this selection stringency and allow the expansion
32 of the higher affinity GC B cells selected, improving the overall response. With a longer dosing
33 interval, the decay in the antigen with time following the prime could further increase the
34 selection stringency, amplifying this effect. The effect remained in our simulations even when
35 new GCs following the boost had to be seeded by memory B cells formed following the prime.
36 These predictions offer a plausible explanation of the observed paradoxical effects of dosage
37 and dosing interval on vaccine efficacy. Tuning the selection stringency in the GCs using
38 prime-boost dosages and dosing intervals as handles may help improve vaccine efficacies.

39 INTRODUCTION

40 The COVID-19 pandemic continues to rage and warrants intensifying the ongoing global
 41 vaccination programs (1, 2). With limited vaccine supplies, it becomes critical to identify
 42 dosing protocols that would maximize vaccine efficacy (3, 4). With the Oxford-AstraZeneca
 43 vaccine, where dosing protocols were adjusted during the trials, data has become available of
 44 the effects of different dosages used for the prime and boost doses and of different intervals
 45 separating them on vaccine efficacy (5-8). A recent study has also examined the effects of
 46 increasing the interval beyond those in the trials (9). Intriguingly, the efficacy in preventing
 47 symptomatic infection was 63.1% when a standard dose (containing 5×10^{10} virus particles) was
 48 used for both prime and boost, whereas the efficacy was substantially higher, 80.7%, when a
 49 low dose prime (containing 2.2×10^{10} virus particles) followed by the standard dose boost was
 50 administered (5). Furthermore, the efficacy increased with the interval between the prime and
 51 boost, from 55.1% at <6 weeks to 81.3% at ≥ 12 weeks, when standard doses were used for
 52 both (5). Inspired by these observations, studies are examining the effects of lower dosages and
 53 increased dosing intervals with other vaccines too, specifically the Pfizer-BioNTech (10-12)
 54 and Moderna (13) vaccines. An understanding of these effects would help identify optimal
 55 dosing protocols and maximize the impact of the ongoing vaccination programs. The origins
 56 of the effects remain to be elucidated.

57 While the role of cellular immunity is yet to be fully elucidated (14), several studies
 58 suggest that the efficacy of currently approved COVID-19 vaccines is attributable to the
 59 neutralizing antibodies they elicit (6, 11, 15-20). The higher efficacies observed above are thus
 60 argued to be due to the improved quality and quantity of the antibodies produced by the

61 associated dosing protocols (5, 8, 9, 11, 21). For instance, higher antibody levels were observed
62 following the boost upon increasing the dosing interval (9, 10). In some cases, antibody-
63 dependent cellular functions too appeared to be better with the longer intervals (21). A question
64 that arises is how the different dosing protocols elicit antibodies of different amounts and
65 affinities for their targets.

66 Antibody production following vaccination (or natural infection) occurs in germinal
67 centers (GCs) (22, 23). GCs are temporary anatomical structures assembled in lymphoid organs
68 where B cells are locally selected based on the ability of their receptors to bind and internalize
69 antigen presented as immune complexes on follicular dendritic cell surfaces in the GCs. (GCs
70 can last anywhere from a few weeks to many months (23-25).) This process, termed affinity
71 maturation, culminates, typically in weeks, in the selection of B cells with affinities that can be
72 several orders of magnitude higher for the target antigen than those at the start of the GC
73 reaction (26, 27). What determines the final affinities is an important question in immunology
74 and is yet to be resolved (28-30). Several studies have identified factors that influence affinity
75 maturation (26, 31-37). A key factor is antigen availability within GCs—related here to the
76 vaccine dosage and antigen half-life—elucidated first by the classic experiments of Eisen and
77 colleagues (26): B cells compete for antigen in the GCs. Their survival depends on how much
78 antigen they acquire, as we explain below. Thus, if antigen is scarce, the selection is stringent
79 and leads to the survival of those B cells that have high affinity for the target antigen. This
80 phenomenon governing the GC reaction is manifested widely, including in the effects of
81 passive immunization following HIV infection, and can be potentially exploited by tuning
82 antigen availability (34, 35, 38, 39).

83 Here, we reasoned that one way in which the effects of the different vaccination
84 protocols could arise was from the influence the protocols had on antigen availability and hence
85 selection stringency within GCs. Specifically, low dose prime is expected to result in low
86 antigen availability and may lead to the selection of higher affinity B cells. The standard dose
87 boost could then enable the expansion of these higher affinity B cells. With a larger dosing
88 interval, the decay of antigen between doses could cause an increase in selection stringency,
89 resulting in a similar effect. To test this hypothesis, we developed a detailed stochastic
90 simulation model of the GC reaction. Such simulation models have been shown to mimic the
91 GC reaction faithfully and have helped resolve confounding experimental observations and
92 predict optimal vaccination protocols (34-36, 39-44).

93

94 **RESULTS**

95 **Stochastic simulation model of the GC reaction post COVID-19 vaccination**

96 We present an overview of the model here (Fig. 1); details are in Methods. We
97 considered individuals who were not previously infected and were administered COVID-19
98 vaccines. We focused on the GC reaction in such individuals. The simulation, building on
99 previous protocols (35, 36, 39, 40, 42), considered and modelled events within an individual
100 GC. The GC reaction is initiated by B cells of low affinity for a target, non-mutating antigen.
101 The target could be a portion of or the entire spike protein of SARS-CoV-2. We simulated the
102 ensuing affinity maturation process using a discrete generation, Wright-Fisher-type, formalism
103 (36, 39). The GC is divided into a light zone and a dark zone (Fig. 1A). The antigen is presented
104 in the light zone and is represented as a bit-string of L amino acids. Each B cell is identified by

its B cell receptor (BCR), which is also represented as a bit-string of L amino acids. The affinity of a B cell for the antigen is determined by the extent of the match between the BCR and antigen sequences (39, 42), defined here using ε . $\varepsilon=0$ if the two sequences are completely distinct, whereas $\varepsilon=L$ if they are identical. The higher the ε , the higher is the affinity. In each generation, we let each B cell have an average of η attempts to acquire antigen. η thus serves as a surrogate of antigen availability in the GC (39). The probability with which a B cell acquires antigen in each attempt is set proportional to its affinity for the antigen (39). If a B cell fails to acquire a minimum amount of antigen, it is assumed to undergo apoptosis (31), and is eliminated. The surviving B cells then compete for help from T follicular helper (T_{fh}) cells. The probability that a B cell receives such help is set proportional to the amount of antigen it has acquired relative to that of the other B cells in the generation (39). B cells that do not succeed in receiving T_{fh} help are again assumed to undergo apoptosis (31). Among the surviving B cells, following previous studies (39), we let 5% exit the GC, become plasma cells, and produce antibodies; 5% exit and become memory B cells; and 90% migrate to the dark zone, where they proliferate and mutate their BCR genes and return to the light zone (39, 43). The latter B cells form the pool for the next generation of the GC reaction. The antibodies produced by plasma cells can feedback into the GC and, by displacing lower affinity antibodies in the immune complexes or by masking antigen, tend to increase the selection stringency (35, 39, 45).

Following dosing, antigen is trafficked to the lymph nodes, where its levels rise rapidly and then decline exponentially (34, 46). Accordingly, we let η rise immediately upon dosing to a pre-determined amount dependent on the vaccine dosage and then decrease with each generation based on the half-life of the administered antigen (Fig. 1B). With the boost, we

127 considered two scenarios (34, 47, 48): the first where the boost enhanced antigen levels in pre-
 128 existing GCs, and the second where it initiated new GCs using memory B cells formed by the
 129 prime.

131 **Figure 1. Schematic of the GC reaction model post vaccination.** (A) The GC reaction. The
 132 antigen from the vaccine enters the GC complexed to antibodies and is presented in the light
 133 zone on the surfaces of follicular dendritic cells attached to FcγRIIB or CR2 receptors. GC B
 134 cells acquire antigen with a probability proportional to their affinity for the antigen. They then

135 receive help from T follicular helper cells with a probability dependent on the relative amount
 136 of antigen they acquired. Cells that fail to acquire antigen or receive the latter help die. Cells
 137 that succeed can exit the GC to become plasma cells and secrete antibodies, become memory
 138 B cells, or migrate to the dark zone, where they proliferate and mutate their antibody genes.
 139 The latter cells circulate back to the light zone and become subjected to the same selection
 140 process. Antibodies secreted by plasma cells can feedback into the GC and affect the selection
 141 process. (B) Schematic of the simulations. (Top) Timeline showing dose administration and
 142 corresponding antigen levels. (Bottom) GCs are formed following the prime and gradually
 143 shrink with time due to decreasing antigen levels. The prime could be low dose (LD) or
 144 standard dose (SD). The boost could restore existing GCs (mechanism I) or lead to new GCs
 145 seeded by memory B cells formed during the prime (mechanism II). The boost is typically SD.

146

147 We also examined the baseline, control scenario where the boost initiated GCs *de novo*,
 148 independently of the prime. We considered vaccination protocols with low and standard dose
 149 prime and a range of prime-boost dosing intervals. We performed multiple stochastic
 150 realizations of the simulations for each vaccination protocol and predicted the expected
 151 antibody response as an indicator of vaccine efficacy.

152

153 **Antigen availability and its effect on selection stringency**

154 To elucidate affinity maturation in the GC reaction, we first performed simulations with
 155 a constant η , set here to 7. (We considered other values of η later.) The GC initially had B cells
 156 with low affinity for the target antigen. As the GC reaction proceeded, B cells with increasing
 157 affinity were selected in our simulations, marking affinity maturation (Fig. 2A). Eventually, a
 158 stationary distribution of B cells of different affinities was achieved, dominated by B cells with
 159 the highest affinities, as observed in previous studies (39) and akin to the mutation-selection
 160 balance observed in other evolutionary simulations (49, 50). We focussed on the corresponding
 161 evolution of the average affinity of the B cells. As the GC reaction progressed, the average

162 affinity of the B cells increased and reached a plateau (Fig. 2B). Thus, when $\eta=7$, the average
 163 affinity of the B cells, determined by the average match-length between the antigen and BCR
 164 sequences, plateaued at ~ 6.7 (Fig. 2B inset). Note that $L=8$ in these simulations.

165
 166 **Figure 2. The effect of antigen availability and half-life on the GC reaction.** (A) Time-
 167 evolution of populations of GC B cells of different affinity, ϵ , for the antigen; $\eta=7$. (B) Time-
 168 evolution of the average affinity of GC B cells for different η . *Inset:* The values at day 21 and
 169 day 80, the latter the plateau values, of the average affinity versus η . (C) Time-evolution of the
 170 affinity-weighted cumulative antibody output for different η . (D) Time-evolution of the
 171 average affinity for different antigen half-lives, τ , and the initial η , $\eta_0=20$. (E) Corresponding
 172 cumulative antibody output. *Insets in (C-E):* Corresponding values at day 80.

To examine the effect of antigen availability, we next performed simulations at different values of η . Increasing η resulted in a lower value of the plateau of the average affinity (Fig. 2B), indicative of weaker selection. Increasing η would correspond to higher vaccine dosages. B cells with lower affinities were selected with higher η because more opportunities were available for antigen acquisition. Thus, the average affinity plateaued at ~ 3.4 when $\eta=15$ and decreased further with larger η (Fig. 2B inset). This is consistent with the classic observations of poorer affinity maturation with increasing antigen levels (26, 39). In terms of the absolute antibody titres, our simulations predicted that unless the selection stringency was so large that the GC B cell population began to decline causing GC collapse (Fig. S1), the GC B cell population was maintained, leading to a steady output of Abs from the GC (Fig. S2). The lower affinity with increasing η thus resulted in a corresponding decrease in the affinity-weighted cumulative antibody output in our simulations (Fig. 2C). The latter output was ~ 417 when $\eta=7$ and ~ 216 when $\eta=15$ at 80 d following dosing (Fig. 2C inset). This affinity-weighted antibody output would serve as a measure of the humoral response elicited by vaccination; it accounts for the effects of both the quality and the quantity of the response. At very high values of η , beyond ~ 20 in our simulations, the effect of varying η was minimal (Fig. 2B and C), indicating that at sufficiently high dosages, the effect of varying dosage on the GC reaction may not be significant. At lower η , between 7 and 15 in our simulations, lowering dosage resulted in a substantial gain in the GC response. When η was too low, however, in our simulations, GCs collapsed, as not enough antigen was available for sustaining the B cell population (Fig. S1).

Following vaccination, antigen levels are expected to decline exponentially with time.

We therefore next performed simulations with η decreasing with a half-life τ ; i.e., $\eta = \eta_0 \exp(-t \times \ln 2 / \tau)$, where η_0 is the peak antigen level achieved soon after dosing. How antigen levels quantitatively decay on follicular dendritic cells within GCs relative to that in plasma is not well understood (34, 51, 52). We therefore examined a range of values of τ . We found in our simulations with $\eta_0 = 20$, that the average affinity was higher when τ was lower (Fig. 2D). Specifically, the average affinity at day 80 from the start of the GC reaction was ~ 6.7 for $\tau = 40$ d and ~ 3.4 for $\tau = 160$ d (Fig. 2D inset). The faster decay of antigen thus increased the selection stringency within the GC and led to higher affinity B cells. The affinity-weighted cumulative antibody output, accordingly, increased with decreasing τ , consistent with an improved response due to increased selection stringency (Fig. 2E).

Prime-boost vaccination: the effect of dosage

We now applied our simulations to mimic the prime-boost vaccination protocols employed in clinical trials (5). Specifically, we considered low dose (which we set using $\eta_0 = 10$) and standard dose ($\eta_0 = 20$) combinations, administered with a dosing interval $\Delta = 28$ d mimicking experimental protocols (5, 6, 21). (Our conclusions are not sensitive to these parameter settings; see Fig. S3) An important aspect of the humoral response associated with multiple antigen dosing that remains unknown is whether the subsequent doses modulate GCs formed following the first dose or seed new GCs. GCs have been observed to persist over extended durations following COVID-19 vaccination (24). (Such persistent GCs have been

seen following natural infection with other viruses too (25).) If the interval Δ is relatively small, one may expect the boost to modulate ongoing GC reactions, as has been suggested previously (34, 39). However, if Δ is large, then the GCs formed by the prime may collapse due to antigen decay before the boost, so that the seeding of new GCs by the boost is more likely. In the latter scenario, the effect of the prime must come from the preferential seeding by memory B cells formed following the prime (47, 48, 53). Recruitment of memory B cells into GCs has been suggested, especially those B cells that displayed cross reactivity to other circulating human betacoronaviruses (24). We therefore simulated two limiting scenarios (Fig. 1B): First, we assumed that the boost modulated existing GCs and seeded no new GCs. Second, we let the boost seed GCs using the memory B cells formed from the prime and not modulate any existing GCs. We also simulated a control case where the boost established new GCs *de novo*, without using memory B cells from the prime, in which case no advantage from the prime is expected.

With the boost modulating existing GCs, our simulations predicted an advantage of the low dose prime over the standard dose prime (blue and red lines in Fig. 3A, B). The average affinity increased with time more steeply with the low dose until day 28, when the boost was administered (Fig. 3A). Just prior to boost administration, the average affinity was ~ 4.9 for the low dose versus ~ 2.8 for the standard dose prime. Correspondingly, the affinity-weighted cumulative antibody output was higher for the low dose than the standard dose (Fig. 3B). The administration of the boost caused an increase in antigen availability (Fig. 3A inset), relieving the selection stringency. The average affinity thus saw a temporary dip (Fig. 3A). However, as affinity maturation continued, the higher affinity B cells selected with the low dose prime expanded substantially, yielding a much higher affinity-weighted antibody output than with the

standard dose prime (Fig. 3B). The average affinity and the affinity-weighted cumulative antibody output was higher with the low dose prime than the standard dose prime throughout our simulations.

240

241

242

Figure 3. Influence of different prime-boost dosages. (A) Time-evolution of the average affinity of GC B cells for different dosing protocols indicated. *Inset*: The associated antigen levels. (B) Time-evolution of the affinity-weighted cumulative antibody output for the cases in (A). *Inset*: Corresponding values at the final simulation time point. Parameters used: $\Delta=28$ d; $\tau=40$ d; $\eta_0=10$ for LD and $\eta_0=20$ for SD.

248

When we let the boost seed GCs using memory B cells from the prime, the difference between low dose and standard dose prime was smaller in our simulations following the boost (green and orange curves in Fig. 3A, B). This is because we assumed that only B cells above a certain affinity for the antigen (here, match length ≥ 3 ; see Methods) could differentiate into memory B cells following stimulation. The advantage of the low dose prime in yielding high affinity B cells was thus reduced. The choice of memory B cells is in keeping with the expectation that low affinity naïve-like B cells may not receive strong enough signals to differentiate into switched memory B cells (54). Also, low affinity B cells are likely to exist

257 regardless and thus seeding GCs with low affinity memory B cells may be no different from
 258 seeding GCs *de novo*. Yet, even within the memory pool, the low dose prime yielded higher
 259 affinity B cells than the standard dose prime, explaining the advantage of the low dose prime
 260 in our simulations (Fig. 3A). The differences in the corresponding affinity-weighted cumulative
 261 antibody output (Fig. 3B) were as expected but commensurately smaller than when the boost
 262 seeded existing GCs. Both scenarios yielded better responses than the control case where the
 263 boost seeded GCs *de novo* (grey lines in Fig. 3A, B).

264

265 **Prime-boost vaccination: the effect of dosing interval**

266 To assess the influence of the dosing interval, we compared next the antibody responses
 267 elicited by two dosing intervals, $\Delta=28$ d and $\Delta=56$ d. We let $\tau=80$ d here to avoid GC collapse
 268 following low dose prime with shorter antigen half-lives (Fig. S4). The average GC B cell
 269 affinity was significantly higher with $\Delta=56$ d than $\Delta=28$ d when the GCs were allowed to persist
 270 until the boost (Fig. 4A, B). For instance, the average affinity was ~ 6.6 and ~ 4.4 , respectively,
 271 in the two cases, just before the administration of the boost following low dose prime, because
 272 affinity maturation continued longer with the longer dosing interval. Besides, the declining
 273 antigen levels further increased selection stringency in the latter case. This qualitative trend
 274 remained with the standard dose prime. The affinity-weighted cumulative antibody output was
 275 also significantly higher with the $\Delta=56$ d than $\Delta=28$ d (Fig. 4C, D). For instance, 28 d after the
 276 boost, the output was ~ 380 and ~ 174 , respectively, in the two cases, when low dose prime was
 277 used and the boost modulated existing GCs. With standard dose prime too, the difference was
 278 nearly 2-fold. This effect remained whether the boost seeded new GCs or modulated surviving

GCs (Fig. 4A-D), indicating a distinct advantage of the longer interval. The cases all yielded significantly better responses than the control case where the boost elicited GCs *de novo* (Fig. 4A-D).

Because the selection stringency depended on antigen half-life, τ , we assessed the effect of varying Δ for a range of values of τ . Following recent experiments (9, 12), we also considered much larger values of Δ ; ranging from 28 d to 84 d (Figs. 4E, F and S4). To evaluate the effect on affinity maturation, we compared the maximum value of the average GC B cell affinity achieved at any time 1 week post the boost (to eliminate transients). We found that at any τ , increasing Δ increased the peak affinity, regardless of the use of low dose or standard dose prime or whether the boost seeded new GCs or affected existing GCs (Fig. 4E). Thus, a longer duration yielded a GC response of better quality. Further, the lower was τ , the higher was the peak affinity at any Δ , consistent with stronger selection stringency associated with lower antigen availability (Fig. 4E).

This latter effect influenced the overall response, combining quality with quantity, which we assessed using the affinity-weighted cumulative antibody output 28 d post the boost (Fig. 4F). While the overall trend of improved output with longer Δ remained, the trend was more nuanced. The nuances were due to the complex dynamics of the GC responses following multiple dosing. We examined first the effect of low dose prime. When τ was large, the GC reaction was sustained longer, allowing greater affinity maturation (Fig. S4). Thus, delayed dosing interval would lead to better responses. Indeed, with $\Delta=56$ d and $\Delta=84$ d, our simulations predicted that the cumulative output improved with τ (Fig. 4F). With $\Delta=28$ d, the GCs may not

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Figure 4. Influence of prime-boost dosing interval. (A, B) Average GC B cell affinities, and (C, D) affinity-weighted Ab outputs, with prime-boost intervals (Δ) of either 28 d (A, C) or 56 d (B, D), and with LD/SD or SD/SD dosing. Bottom inset of (A): LD and SD correspond to $\eta_0=10$ and 20, respectively, with $\tau=80$ d. Top insets in (A-D): values at the final time point. Heatmaps of (E) the maximum GC affinity recorded between 1 week post boost administration and the final time point, and (F) the affinity-weighted cumulative Ab output 28 d post the boost, as a function of τ (20, 40 and 80 d) and Δ (4, 8, and 12 weeks) for the two limiting scenarios (Mem. reseed and Cont. GC). Trajectories corresponding to the heatmaps are shown in Figure S4. Black regions in (E) correspond to collapsed GCs. A heatmap of the affinity-weighted cumulative Ab output 56 d post the boost is shown in Figure S4C.

311

have expanded sufficiently before the boost. With low τ , leading to high selection stringency, GCs tended to collapse after the boost (Fig. S4). With large τ , the selection stringency was weaker and it therefore took longer for affinities to rise. Consequently, intermediate τ yielded the best response (Fig. 4F).

With standard dose prime, too, the effects were similar. The GCs were sustained longer as τ increased, but weaker selection due to greater antigen availability led to poorer affinity maturation (Fig. S4). The trade-off tended to yield the best response at intermediate τ . In our simulations, when the boost contributed to existing GCs, it was not efficient in rescuing GCs that were beginning to collapse. Thus, with low and intermediate τ , GCs tended to collapse (Fig. S4). When the boost was assumed to seed new GCs using memory cells from the prime, because the latter had higher affinities for the antigen, the GCs not only survived, but also expanded. The benefit was amplified with delayed dosing as better memory cells became available for seeding the GCs. Thus, as long as τ was not too small, the cumulative output tended to improve with increasing Δ (see $\tau=40$ d and 80 d in Fig. 4F). (With very small τ , the increased GC collapse compromised the response at high Δ ; see $\tau=20$ d in Fig. 4F). These

trends were maintained when the output was considered 56 d post boost (Fig. S4). That GCs following COVID-19 vaccination can persist over extended durations (24) suggests that GC shrinkage may be slow *in vivo*. Large dosing intervals would then improve responses, as has been observed in clinical trials (9).

DISCUSSION

Understanding the reasons behind the improved efficacy of COVID-19 vaccines upon delaying the boost dose or using a low dose prime would aid optimal deployment of vaccines, critical to settings with limited supplies. Here, using comprehensive stochastic simulations of the GC reaction post vaccination, we elucidated plausible mechanistic origins of the improved efficacy. To our knowledge, ours is the first study to employ such simulations to assess the influence of COVID-19 vaccination protocols. The GC reaction is constrained by a quality-quantity trade-off (26, 34, 35, 39): Lower antigen availability in the GC leads to more stringent B cell selection, resulting in the production of higher affinity antibodies but in smaller amounts. Increasing antigen availability reverses these effects. The different dosing protocols used—low versus standard dose prime and different dosing intervals—affect this trade-off. With low dose prime, antigen availability in the GCs is lowered, resulting in the selection of high affinity GC B cells. The boost relaxes the selection stringency and allows the expansion of the selected B cells. Delaying the boost delays the relaxation, resulting in even higher affinity B cells getting selected following the prime. Following the boost, these latter B cells would result in better overall GC responses, explaining the observed improvements in efficacy.

Experimental evidence supports the above reasons. Antibody titres targeting the SARS-CoV-2 spike were measured in individuals administered the boost 8-12 weeks, 15-25 weeks, and 44-45 weeks after the prime (9). The titres were consistently higher in the individuals with the longer dosing intervals. However, interestingly, the titres just before the boost, were lower in the individuals with the longer intervals. This was consistent with lower antibody output due to declining antigen availability with time in the GC and the associated GC shrinkage. Furthermore, the higher corresponding selection stringency may have resulted in the selection of GC B cells and memory B cells with higher affinity, which would be expected to rescue shrinking GCs or seed new GCs better, explaining the better responses eventually observed. Improved antibody responses following delayed boost dosing has now been observed with multiple vaccines (9-12).

With dosing intervals smaller than 8-12 weeks or with the low dose prime, the differences in antibody titres have been less apparent (5, 8, 21). Yet, the improvement in vaccine efficacy is substantial (5). While we have argued that this improvement may be due to the improved affinity of the antibodies, direct measurements of affinity are lacking. *In vitro* pseudo-typed virus neutralization efficiency of antibodies isolated 28 d after the boost were not significantly different between individuals administered the low dose prime or the standard dose prime or when both standard doses were administered with a 28 d or 56 d interval (5, 8, 21). It is possible that the improvements in affinity may not be adequate to be manifested as improved *in vitro* neutralization efficiencies, possibly because the stoichiometry of antibody binding to the viral spike proteins that ensures virus neutralization (55-57), which is yet to be estimated for SARS-CoV-2, may be realized in both scenarios. *In vitro* neutralization

efficiencies tend to be much higher than corresponding *in vivo* efficiencies (58). Nonetheless, greater affinity maturation with lower antigen availability has been long recognized as a hallmark of the GC reaction (26, 34, 35, 39). In independent studies on HIV vaccination, for instance, protocols that allowed antigen levels to rise with time, akin to low dose prime followed by standard dose boost examined here, elicited better antibody responses than protocols that held the antigen levels constant or allowed them to decline with time (34), an effect consistent with the dosing protocols modulating antigen availability and the associated quality-quantity trade-off in the GCs (39).

Our simulations predicted a role for antigen half-life in the response to vaccination. With longer half-lives, the response improved upon increasing the dosing interval. With shorter half-lives, if associated GC shrinkage was too drastic before the administration of the boost, the response following the boost was compromised. Shorter dosing intervals then elicited the best response. We note here that the antigen half-life in the GC may be difficult to estimate (34, 51, 52). That GC B cells and plasmablasts were detectable in high frequencies even 12 weeks after the boost suggests that antigen presented by COVID-19 vaccines may be much longer lasting in the GCs than expected from their half-life in circulation (24). Such prolonged GC responses have been observed in other settings (25). Future studies may yield accurate estimates of the antigen half-life in GCs, which would help identify optimal dosing intervals for the different COVID-19 vaccines available.

Quantitative comparison of our predictions with experimental observations is difficult, as has been the case with other modeling studies of the GC reaction (34-36, 39, 40, 42, 45). This is because a number of key biological processes associated with the GC reaction remain

392 to be elucidated, including the link between dosage and the number of GCs seeded, and between
 393 measurable antigen levels in circulation and those within individual GCs (22, 23, 34, 35, 39).
 394 Only recently have these links begun to be evaluated (37). As a simplification, our simulations
 395 have assumed that increased dosage leads to increased antigen availability within GCs while
 396 keeping the number of GCs seeded fixed. It is possible that the number of GCs seeded may
 397 also increase with dosage but with a commensurately smaller rise in the antigen levels per GC.
 398 Future studies that elucidate the links above may help define these quantities better.
 399 Nonetheless, the poorer quality of the antibody response with increasing dosage is a widely
 400 observed and accepted phenomenon (26, 34, 39), giving us confidence in our findings.

401 We recognize that other arms of the immune system that could be triggered by the
 402 vaccines, particularly T cells, may affect the vaccine efficacies realized (5-9, 13, 14). The
 403 strength and timing of the T cell response has been argued to be important in determining the
 404 severity of the infection (59), which in turn may affect the estimated vaccine efficacy (60). We
 405 have focused here on the antibody response, to which the efficacies have been found to be
 406 strongly correlated (18, 19, 60), and which in our simulations qualitatively explained the effects
 407 of the different dosing protocols on vaccine efficacies.

408 Other hypotheses have been proposed to explain the effects of low dose prime and
 409 delayed dosing intervals, the predominant of which has been the undesirable response to the
 410 adenoviral vector in the case of the Oxford/AstraZeneca vaccine that could blunt the response
 411 to the boost (61). While these hypotheses remain to be tested, that the effects are now evident
 412 with more than one vaccine, including lipid nanoparticle mRNA vaccines that do not use the

adenoviral vectors (10-13), suggests that the effects are intrinsic to the responses elicited by the SARS-CoV-2 antigens in the vaccines, supporting our hypothesis.

In summary, our study offers an explanation of the confounding effects of different dosages and dosing protocols on COVID-19 vaccine efficacies. The resulting insights would inform studies aimed at designing optimal vaccine deployment strategies.

METHODS

Stochastic simulations of the GC reaction

We developed the following *in silico* stochastic simulation model of the GC reaction (Fig. 1A). The model builds on a previous study which examined the role of passive immunization on the GC reaction (39). Here, we adapted it describe the effect of COVID-19 vaccination.

Initialization. We initiated the GC reaction with $N=1000$ GC B cells of low affinity for the target antigen in the light zone of the GC. This follows observations where low affinity seeder B cells initiate the GC reaction by proliferating rapidly to a steady state size of 1000 cells, following which somatic hypermutation and affinity maturation commence (36, 39). We considered a non-mutating antigen, determined by a randomly chosen string of length L and alphabet of size $\kappa=4$. The alphabet size represents the broad classes of amino acids, namely, positively charged, negatively charged, polar, and hydrophobic (42). The B cell receptor (BCR) paratope for each cell is then set by randomly mutating the antigen sequence at $L-1$ randomly chosen positions. This ensured that the cells in the initial pool all had low affinities for the antigen. The B cells were then allowed to acquire antigen.

Antigen acquisition. Antigen is presented to B cells as antibody-bound immune complexes on follicular dendritic cell surfaces. The probability with which a B cell successfully acquired the antigen was $f_{Ag} = (\varepsilon - \omega + L) / 2L$, where ε and ω are the lengths of the longest common substrings of the antigen sequence and those of the associated B cell receptor (BCR) and the presenting antibody, respectively. The latter expression followed from a mechanistic consideration of bond dissociation triggered by the competition between the BCR and the antibody for the antigen (39). Note that antibodies are secreted versions of the BCRs and hence were similarly represented as bit-strings of length L too. The presenting antibodies were produced by plasma cells and re-entered the GC via antibody feedback, described below. B cells were selected at random for antigen acquisition, with each B cell selected η times on average. The amount of antigen acquired by a B cell was set equal to the number of successful acquisition attempts, denoted as θ . B cells had to acquire a minimum amount of antigen, denoted θ_c , for them to survive. Surviving cells were eligible to receive help from T follicular helper (T_{fh}) cells. We capped the level of antigen acquired at θ_∞ , at which point the B cell may have received saturating levels of stimulatory signals necessary for T_{fh} cell help.

T_{fh} cell help. We chose surviving B cells randomly and let each cell receive T_{fh} cell help with the probability $f_T = (\theta - \theta_{\min}) / (\theta_{\max} - \theta_{\min})$, where $\theta_{\min}$ is the minimum antigen acquired by the surviving B cells and $\theta_{\max} (= \min(\eta, \theta_\infty))$ is the maximum antigen acquired. The probability follows from the recognition that T_{fh} cell help depends on the relative and not absolute amount of antigen acquired (23, 39). Cells that do not receive help died. We continued this with every surviving cell and stopped if 250 cells successfully received T_{fh} help.

456 **Cell fate decision.** Of the cells selected above, we chose 5% randomly to become memory B
457 cells; 5% to become plasma cells; and the rest to migrate to the dark zone of the GC. The
458 memory B cells were constrained to have a minimum affinity for the antigen (54) (here, match
459 length 3) and were allowed to survive long-term. The plasma cells exited the GC, commenced
460 producing antibodies, and died at the rate of 0.015 per generation (Table S1).

461 **Proliferation and mutation.** The cells in the dark zone were allowed to multiply, with each
462 cell dividing twice. Of the resulting cells, we chose 10% and introduced single random point
463 mutations in their BCR sequences. The latter frequency was chosen following estimates based
464 on the somatic hypermutation frequency suggesting that 1 in 10 GC B cells would be mutated
465 per generation in their antibody variable region genes (23, 36, 39, 42). The two divisions per
466 cell would bring the cell population back to the $N \sim 1000$ cells. This completed one generation
467 of B cell evolution in the GC.

468 **Recycling.** The resulting cells in the dark zone were all allowed to migrate to the light zone,
469 offering the next generation of cells on which the above process would repeat.

470 **Antibody feedback.** Antibodies produced by plasma cells could traffic back to the GC and
471 influence antigen presentation (35). Accordingly, following estimated trafficking timescales,
472 we let antibodies produced by plasma cells in any generation become the antibodies presenting
473 antigen to B cells two generations later (35, 39). Antibodies were also systemically cleared at
474 the rate of 0.01165 per generation (Table S1).

475 **Termination.** We repeated the above process for up to 250 generations (~18 weeks) or if the
476 cell population declined, leading to GC collapse.

477

478 **Dosing protocol**

479 We implemented the prime-boost dosing protocol by letting η vary with time as
 480 $\eta = \eta_0 \exp(-t \times \ln 2 / \tau)$, mimicking antigen rise immediately upon dosing (to η_0) and an exponential
 481 decline subsequently with half-life τ (34, 39, 46). The decline is assumed to subsume any loss
 482 of antigen due to acquisition by B cells. We set η_0 based on whether a low or standard dose
 483 was employed. The prime and boost were separated by the duration Δ . Our interest is in large
 484 values of Δ and low first dosages, so that at the time of boost administration, the residual antigen
 485 is small. Whether memory B cells seed GCs post boost is a topic of active current research (47,
 486 48, 53, 54, 62, 63). We therefore considered all potential scenarios, with the boost 1) feeding
 487 into existing GCs; 2) seeding new GCs using memory B cells; 3) seeding new GCs using naïve
 488 B cells. In scenario 2, we let the memory B cells for seeding the GCs be chosen with a
 489 probability proportional to their affinity for the antigen. In other words, the distribution of B
 490 cells of different affinities in the seeder pool mimics the distribution of affinity-weighted
 491 fractions of memory B cells formed following the prime.

492

493 **Parameter values**

494 The parameter values employed and their sources are listed in Table S1.

495

496 **Quantification of the GC response**

497 With each parameter setting, we performed 2500 realizations, which we divided into 25
 498 ensembles of 100 GC realizations each (39). The average GC B cell affinity in the g^{th} generation
 499 was calculated using,

$$\alpha(g) = \left\langle \frac{\sum_{i=1}^{100} \sum_{j=1}^{n_i(g)} a_{ij}(g)}{\sum_{i=1}^{100} n_i(g)} \right\rangle_{25}$$

where a_{ij} was the affinity of the j^{th} B cell among the $n_i(g)$ B cells in the g^{th} generation of the i^{th} realization of an ensemble. The angular brackets represent averaging across the ensembles. The affinity-weighted plasma cell output in the g^{th} generation was

$$w(g) = \left\langle \sum_{i=1}^{100} \sum_{\varepsilon=1}^L p_{\varepsilon}^i(g) \frac{\varepsilon}{L} \right\rangle_{25}$$

where $p_{\varepsilon}^i(g)$ was the number of plasma cells with affinity ε in the g^{th} generation. If plasma cells died at the per capita rate δ_p , then the affinity-weighted cumulative plasma cell output would be

$$P(g) = \sum_{\varphi=1}^g w(\varphi) \exp(-\delta_p(g - \varphi)).$$

If the antibody production rate of plasma cells was β per generation (64), the instantaneous affinity-weighted antibody output would be $\beta P(g)$, which given the clearance rate, δ_A , of circulating antibodies yielded the affinity-weighted cumulative antibody output as

$$\gamma(g) = \sum_{\varphi=1}^g \beta P(\varphi) \exp(-\delta_A(g - \varphi)).$$

We performed the simulations and analysed the results using programs written in MATLAB.

COMPETING INTERESTS

The authors declare that no conflicts of interests exist.

518 REFERENCES

- 519 1. O. J. Wouters *et al.*, Challenges in ensuring global access to COVID-19 vaccines: production,
520 affordability, allocation, and deployment. *Lancet* **397**, 1023-1034 (2021).
- 521 2. G. Forni, A. Mantovani, COVID-19 vaccines: where we stand and challenges ahead. *Cell Death*
522 *Differ* **28**, 626-639 (2021).
- 523 3. C. M. Saad-Roy *et al.*, Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine
524 dosing regimes. *Science* 10.1126/science.abg8663 (2021).
- 525 4. K. M. Bubar *et al.*, Model-informed COVID-19 vaccine prioritization strategies by age and
526 serostatus. *Science* **371**, 916-921 (2021).
- 527 5. M. Voysey *et al.*, Single-dose administration and the influence of the timing of the booster dose on
528 immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four
529 randomised trials. *Lancet* **397**, 881-891 (2021).
- 530 6. M. Voysey *et al.*, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-
531 CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
532 *Lancet* **397**, 99-111 (2021).
- 533 7. P. M. Folegatti *et al.*, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-
534 CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet* **396**,
535 467-478 (2020).
- 536 8. M. N. Ramasamy *et al.*, Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a
537 prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled,
538 phase 2/3 trial. *Lancet* **396**, 1979-1993 (2021).
- 539 9. A. Flaxman *et al.*, Tolerability and immunogenicity after a late second dose or a third dose of
540 ChAdOx1 nCoV-19 (AZD1222). *Preprint* 10.2139/ssrn.3873839.,
541 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3873839 (2021).
- 542 10. H. Parry *et al.*, Extended interval BNT162b2 vaccination enhances peak antibody generation in older
543 people. *medRxiv* 10.1101/2021.05.15.21257017, 2021.2005.2015.21257017 (2021).
- 544 11. H. Victoria *et al.*, Delayed interval BNT162b2 mRNA COVID-19 vaccination provides robust
545 immunity. *Nature Portfolio* 10.21203/rs.3.rs-793234/v1 (2021).
- 546 12. R. Payne *et al.* (2021) Sustained T cell immunity, protection and boosting using extended dosing
547 intervals of BNT162b2 mRNA vaccine. [https://www.pitch-](https://www.pitch-study.org/PITCH_Dosing_Interval_23072021.pdf)
548 [study.org/PITCH_Dosing_Interval_23072021.pdf](https://www.pitch-study.org/PITCH_Dosing_Interval_23072021.pdf)
- 549 13. J. Mateus *et al.*, Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and
550 antibodies enhanced by pre-existing crossreactive T cell memory. *medRxiv*
551 10.1101/2021.06.30.21259787, 2021.2006.2030.21259787 (2021).
- 552 14. M. Sadarangani, A. Marchant, T. R. Kollmann, Immunological mechanisms of vaccine-induced
553 protection against COVID-19 in humans. *Nat Rev Immunol* **21**, 475-484 (2021).
- 554 15. L. R. Baden *et al.*, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med* **384**,
555 403-416 (2021).
- 556 16. D. Y. Logunov *et al.*, Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-
557 boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
558 *Lancet* **397**, 671-681 (2021).
- 559 17. F. P. Polack *et al.*, Safety and efficacy of the BNT162b2 mRNA COVID-19 Vaccine. *N Engl J Med*
560 **383**, 2603-2615 (2020).
- 561 18. D. S. Khoury *et al.*, Neutralizing antibody levels are highly predictive of immune protection from
562 symptomatic SARS-CoV-2 infection. *Nat Med* 10.1038/s41591-021-01377-8 (2021).
- 563 19. K. A. Earle *et al.*, Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine*
564 **39**, 4423-4428 (2021).
- 565 20. F. Krammer, A correlate of protection for SARS-CoV-2 vaccines is urgently needed. *Nat Med* **27**,
566 1147-1148 (2021).

- 567 21. J. R. Barrett *et al.*, Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose
568 induces multifunctional antibody responses. *Nat Med* **27**, 279-288 (2021).
- 569 22. J. G. Cyster, C. D. C. Allen, B cell responses: cell interaction dynamics and decisions. *Cell* **177**, 524-
570 540 (2019).
- 571 23. G. D. Victora, M. C. Nussenzweig, Germinal centers. *Annu Rev Immunol* **30**, 429-457 (2012).
- 572 24. J. S. Turner *et al.*, SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.
573 *Nature* 10.1038/s41586-021-03738-2 (2021).
- 574 25. C. W. Davis *et al.*, Longitudinal analysis of the human B cell response to Ebola virus infection. *Cell*
575 **177**, 1566-1582.e1517 (2019).
- 576 26. H. N. Eisen, G. W. Siskind, Variations in affinities of antibodies during the immune response.
577 *Biochemistry* **3**, 996-1008 (1964).
- 578 27. M. Bonsignori *et al.*, Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic
579 antibody. *Cell* **165**, 449-463 (2016).
- 580 28. J. Foote, H. N. Eisen, Kinetic and affinity limits on antibodies produced during immune responses.
581 *Proc Natl Acad Sci U S A* **92**, 1254-1256 (1995).
- 582 29. J. Foote, H. N. Eisen, Breaking the affinity ceiling for antibodies and T cell receptors. *Proc Natl Acad*
583 *Sci U S A* **97**, 10679-10681 (2000).
- 584 30. R. Desikan, R. Antia, N. M. Dixit, Physical 'strength' of the multi-protein chain connecting immune
585 cells: Does the weakest link limit antibody affinity maturation? *Bioessays* **43**, e2000159 (2021).
- 586 31. J. M. Tas *et al.*, Visualizing antibody affinity maturation in germinal centers. *Science* **351**, 1048-1054
587 (2016).
- 588 32. E. Natkanski *et al.*, B cells use mechanical energy to discriminate antigen affinities. *Science* **340**,
589 1587-1590 (2013).
- 590 33. K. Kwak *et al.*, Intrinsic properties of human germinal center B cells set antigen affinity thresholds.
591 *Sci Immunol* **3** (2018).
- 592 34. H. H. Tam *et al.*, Sustained antigen availability during germinal center initiation enhances antibody
593 responses to vaccination. *Proc Natl Acad Sci U S A* **113**, E6639-E6648 (2016).
- 594 35. Y. Zhang *et al.*, Germinal center B cells govern their own fate via antibody feedback. *J Exp Med* **210**,
595 457-464 (2013).
- 596 36. S. Wang *et al.*, Manipulating the selection forces during affinity maturation to generate cross-reactive
597 HIV antibodies. *Cell* **160**, 785-797 (2015).
- 598 37. Y. Kato *et al.*, Multifaceted effects of antigen valency on B cell response composition and
599 differentiation in vivo. *Immunity* **53**, 548-563 e548 (2020).
- 600 38. T. Schoofs *et al.*, HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses
601 against HIV-1. *Science* **352**, 997-1001 (2016).
- 602 39. A. K. Garg, R. Desikan, N. M. Dixit, Preferential presentation of high-affinity immune complexes in
603 germinal centers can explain how passive immunization improves the humoral response. *Cell Rep* **29**,
604 3946-3957 e3945 (2019).
- 605 40. R. J. De Boer, A. S. Perelson, How germinal centers evolve broadly neutralizing antibodies: The
606 breadth of the follicular helper T cell response. *J Virol* **91** (2017).
- 607 41. M. Meyer-Hermann *et al.*, A theory of germinal center B cell selection, division, and exit. *Cell Rep* **2**,
608 162-174 (2012).
- 609 42. S. Luo, A. S. Perelson, Competitive exclusion by autologous antibodies can prevent broad HIV-1
610 antibodies from arising. *Proc Natl Acad Sci U S A* **112**, 11654-11659 (2015).
- 611 43. M. Oprea, A. S. Perelson, Somatic mutation leads to efficient affinity maturation when centrocytes
612 recycle back to centroblasts. *J Immunol* **158**, 5155-5162 (1997).
- 613 44. T. B. Kepler, A. S. Perelson, Cyclic re-entry of germinal center B cells and the efficiency of affinity
614 maturation. *Immunol Today* **14**, 412-415 (1993).
- 615 45. V. I. Zarnitsyna, J. Lavine, A. Ellebedy, R. Ahmed, R. Antia, Multi-epitope models explain how pre-
616 existing antibodies affect the generation of broadly protective responses to influenza. *PLoS Pathog*
617 **12**, e1005692 (2016).

- 618 46. K. A. Pape, D. M. Catron, A. A. Itano, M. K. Jenkins, The humoral immune response is initiated in
619 lymph nodes by B cells that acquire soluble antigen directly in the follicles. *Immunity* **26**, 491-502
620 (2007).
- 621 47. K. A. Pape, M. K. Jenkins, Do memory B cells form secondary germinal centers?: it depends. *Cold*
622 *Spring Harb Perspect Biol* **10**, a029116 (2018).
- 623 48. M. J. Shlomchik, Do memory B cells form secondary germinal centers?: yes and no. *Cold Spring*
624 *Harb Perspect Biol* **10**, a029405 (2018).
- 625 49. K. Tripathi, R. Balagam, N. K. Vishnoi, N. M. Dixit, Stochastic simulations suggest that HIV-1
626 survives close to its error threshold. *PLoS Comput Biol* **8**, e1002684 (2012).
- 627 50. S. Gadhamsetty, N. M. Dixit, Estimating frequencies of minority nevirapine-resistant strains in
628 chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a
629 mathematical model. *J Virol* **84**, 10230-10240 (2010).
- 630 51. B. A. Heesters, C. E. van der Poel, A. Das, M. C. Carroll, Antigen presentation to B cells. *Trends*
631 *Immunol* **37**, 844-854 (2016).
- 632 52. B. A. Heesters, R. C. Myers, M. C. Carroll, Follicular dendritic cells: dynamic antigen libraries. *Nat*
633 *Rev Immunol* **14**, 495-504 (2014).
- 634 53. L. J. McHeyzer-Williams, C. Dufaud, M. G. McHeyzer-Williams, Do memory B cells form
635 secondary germinal centers?: impact of antibody class and quality of memory T-cell help at recall.
636 *Cold Spring Harb Perspect Biol* **10**, a028878 (2018).
- 637 54. F. Weisel, M. Shlomchik, Memory B cells of mice and humans. *Ann Rev Immunol* **35**, 255-284
638 (2017).
- 639 55. O. F. Brandenburg *et al.*, Predicting HIV-1 transmission and antibody neutralization efficacy in vivo
640 from stoichiometric parameters. *PLoS Pathog* **13**, e1006313 (2017).
- 641 56. S. N. Mulampaka, N. M. Dixit, Estimating the threshold surface density of Gp120-CCR5 complexes
642 necessary for HIV-1 envelope-mediated cell-cell fusion. *PLoS One* **6**, e19941 (2011).
- 643 57. P. Padmanabhan, N. M. Dixit, Mathematical model of viral kinetics in vitro estimates the number of
644 E2-CD81 complexes necessary for hepatitis C virus entry. *PLoS Comput Biol* **7**, e1002307 (2011).
- 645 58. M. J. van Gils, R. W. Sanders, In vivo protection by broadly neutralizing HIV antibodies. *Trends*
646 *Microbiol* **22**, 550-551 (2014).
- 647 59. B. Chatterjee, H. S. Sandhu, N. M. Dixit, The relative strength and timing of innate immune and CD8
648 T-cell responses underlie the heterogeneous outcomes of SARS-CoV-2 infection. *medRxiv*
649 10.1101/2021.06.15.21258935, 2021.2006.2015.21258935 (2021).
- 650 60. P. Padmanabhan, R. Desikan, N. M. Dixit, Modelling the population-level protection conferred by
651 COVID-19 vaccination. *medRxiv* 10.1101/2021.03.16.21253742, 2021.2003.2016.21253742 (2021).
- 652 61. E. Callaway, Why Oxford's positive COVID vaccine results are puzzling scientists. *Nature* **588**, 16-
653 18 (2020).
- 654 62. L. Mesin *et al.*, Restricted clonality and limited germinal center reentry characterize memory B cell
655 reactivation by boosting. *Cell* **180**, 92-106.e111 (2020).
- 656 63. C. Viant *et al.*, Antibody affinity shapes the choice between memory and germinal center B cell fates.
657 *Cell* **183**, 1298-1311.e1211 (2020).
- 658 64. K. Roberts, B. Alberts, A. Johnson, P. Walter, T. Hunt, Molecular biology of the cell. 4th edition. *New*
659 *York: Garland Science* (2002).

660

661 **Supplementary Materials for**

662

663 **Low dose prime and delayed boost can improve COVID-19 vaccine efficacies by**
664 **increasing B cell selection stringency in germinal centres**

665

666 Amar K. Garg^{1,#}, Soumya Mittal¹, Pranesh Padmanabhan², Rajat Desikan^{1,‡}, Narendra M. Dixit^{1,3,*}

667

668 ¹Department of Chemical Engineering, Indian Institute of Science, Bangalore, India 560012

669 ²Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland,
670 Brisbane, Australia 4072

671 ³Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore, India 560012

672 [#]Current Address: Helmholtz Centre for Infection Research, Braunschweig, Germany

673 [‡]Current Address: Certara QSP, Certara UK Limited, Sheffield, UK

674

675 ***Correspondence:**

676 Narendra M. Dixit

677 Email: narendra@iisc.ac.in

678

Figure S1. Influence of η . Time series of (A) GC B cell population and (B) percent surviving GCs for simulations with various η . GCs with low η ($=5$ here) have high rates of apoptosis which result in GCs gradually being extinguished with time. However, these GCs also exhibit accelerated affinity maturation (C) due to the higher selection stringencies. Insets: values at the final time point.

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Figure S2. Absolute Ab output. Unweighted cumulative antibody output at the final time point for various (A) η , and (B) τ . Insets: time series. The curves for the different cases overlap.

Figure S3. Influence of initial Ag levels (dose) and the prime-boost dosing interval (Δ). (A) Average GC B cell affinity, and (B) affinity-weighted Ab output with a prime-boost interval $\Delta=28$ d and antigen half-life $\tau=40$ d, either with LD/SD or SD/SD dosing (LD and SD correspond to $\eta_0=15$ and 30, respectively). These trends are qualitatively similar to those in Figure 3. (C) Average GC B cell affinity, and (D) affinity-weighted Ab output with $\Delta=56$ d and $\tau=40$ d, either with LD/SD or SD/SD dosing (LD and SD correspond to the default $\eta_0=10$ and 20, respectively). Insets: values at the final time point.

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

709 **Figure S4. Influence of the prime-boost dosing interval (Δ).** Time series of (A) average GC
710 B cell affinities, and (B) affinity-weighted Ab outputs corresponding to the heatmaps in Figure
711 4E and 4F, respectively. (C) Heatmaps of the affinity-weighted cumulative Ab output 56 d post
712 the boost, as a function of τ (20, 40 and 80 d) and Δ (4, 8, and 12 weeks) for the two limiting
713 scenarios (Mem. reseed and Cont. GC).

714
715

716 **Table S1. Model parameters and their values.**

<i>Symbol</i>	<i>Description</i>	<i>Value (units)</i>	<i>Refs.</i>
N	Number of B cells initiating the GC reaction	1000 (cells)	(36, 39)
L	String length of antigen, B cell receptor (BCR), and antibody	8 (dimensionless)	(39, 42)
κ	Alphabet size for strings	4 (dimensionless)	(39, 42)
θ_c	Minimum amount of acquired antigen for B cell survival	3 (dimensionless)	(39)
θ_∞	Maximum amount of antigen that can be acquired by a B cell	5 (dimensionless)	-
δ_p	Clearance rate of plasma cells	0.015 (generation ⁻¹)	(34, 44)
β	Antibody production rate of plasma cells per generation	2000 (molecules cell ⁻¹ s ⁻¹)	(64)
δ_a	Clearance rate of antibodies	0.01165 (generation ⁻¹)	(34, 44)

717

718

719